Stocks KRRO

Raymond James Upgrades Korro Bio (KRRO)

Fintel reports that on March 13, 2026, Raymond James upgraded their outlook for Korro Bio (NasdaqCM:KRRO) from Market Perform to Outperform.

Analyst Price Forecast Suggests 52.54% Upside

As of February 25, 2026, the average one-year price target for Korro Bio is $19.53/share. The forecasts range from a low of $8.08 to a high of $31.50. The average price target represents an increase of 52.54% from its latest reported closing price of $12.80 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Korro Bio is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.07.

What is the Fund Sentiment?

There are 107 funds or institutions reporting positions in Korro Bio. This is an decrease of 79 owner(s) or 42.47% in the last quarter. Average portfolio weight of all funds dedicated to KRRO is 0.40%, an increase of 0.34%. Total shares owned by institutions decreased in the last three months by 29.01% to 7,536K shares. KRRO / Korro Bio, Inc. Put/Call Ratios The put/call ratio of KRRO is 1.28, indicating a bearish outlook.

What are Other Shareholders Doing?

Atlas Venture Life Science Advisors holds 1,137K shares representing 11.46% ownership of the company. No change in the last quarter.

NEA Management Company holds 1,091K shares representing 11.00% ownership of the company. No change in the last quarter.

Lynx1 Capital Management holds 678K shares representing 6.83% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.

Nantahala Capital Management holds 600K shares representing 6.05% ownership of the company.

Qiming U.S. Ventures Management holds 368K shares representing 3.71% ownership of the company. No change in the last quarter.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

Fintel
Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford.
Check out our Unique Analysis of Insider Sentiment for Korro Bio, Inc. Find out what the Options Markets think of Korro Bio, Inc. See our take on Korro Bio, Inc. Upcoming Earnings More articles by this source

Tags

Stocks Mentioned

Latest Articles

Data is currently not available